Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board | Zendy

P Bertolotti | Zendy; Elizabeth Bilotti | Zendy; Kathleen Colson | Zendy; Kathleen M. Curran | Zendy; Deborah Doss | Zendy; Beth Faiman | Zendy; Maria Gavino | Zendy; Bonnie Jenkins | Zendy; K Lilleby | Zendy; Ginger Love | Zendy; Patricia Mangan | Zendy; Emily McCullagh | Zendy; Teresa Miceli | Zendy; Kena C. Miller | Zendy; Kathryn Rogers | Zendy; Sandra Rome | Zendy; Stacey Sandifer | Zendy; Lisa C. Smith | Zendy; Joseph D Tariman | Zendy; Jeanne Westphal | Zendy

Open Access

Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation's Nurse Leadership Board

Author(s) -

P Bertolotti,

Elizabeth Bilotti,

Kathleen Colson,

Kathleen M. Curran,

Deborah Doss,

Beth Faiman,

Maria Gavino,

Bonnie Jenkins,

K Lilleby,

Ginger Love,

Patricia Mangan,

Emily McCullagh,

Teresa Miceli,

Kena C. Miller,

Kathryn Rogers,

Sandra Rome,

Stacey Sandifer,

Lisa C. Smith,

Joseph D Tariman,

Jeanne Westphal

Publication year - 2008

Publication title -

clinical journal of oncology nursing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.375

H-Index - 43

eISSN - 1538-067X

pISSN - 1092-1095

DOI - 10.1188/08.cjon.s1.9-12

Subject(s) - medicine , multiple myeloma , grading (engineering) , foundation (evidence) , intensive care medicine , family medicine , oncology , nursing , civil engineering , archaeology , engineering , history

Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research